(Q58622847)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11155152%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

meta-analysis

0 references

title

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11155152%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

0 references

1 reference

1 reference

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11155152%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

author name string

Thévenot T

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11155152%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Regimbeau C

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11155152%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Ratziu V

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11155152%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Leroy V

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11155152%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

Opolon P

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11155152%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

publication date

1 January 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11155152%20AND%20SRC:MED&resulttype=core&format=json

Journal of Viral Hepatitis

3 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11155152%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11155152%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11155152%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

48-62

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11155152%20AND%20SRC:MED&resulttype=core&format=json

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration

3 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Meta-analyses of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

The retrieval of randomized clinical trials in liver disease from the medical literature. A comparison of MEDLARS and manual methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Methods for combining randomized clinical trials: strengths and limitations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Randomised trial of lymphoblastoid alpha-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Treatment of chronic sporadic-type non-A, non-B hepatitis with lymphoblastoid interferon: gamma GT levels predictive for response

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alfa-2b: Swedish experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

A randomized controlled trial of interferon-alpha in patients with cirrhosis caused by 2a/2b genotype hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Human lymphoblastoid interferon treatment for patients with hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C. The TVVH Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Treatment of chronic hepatitis C with interferon alfa-n3: a multicenter, randomized, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Virological, biochemical and histological effects of human lymphoblastoid interferon in Swedish patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Hepatic stellate (ITO) cells: expanding roles for a liver-specific pericyte

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Comparative study of two high doses of lymphoblastoid interferon in the treatment of chronic hepatitis C: influence on the levels of ALT, viraemia and histologic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Viral and host factors that contribute to efficacy of interferon-alpha 2a therapy in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

New approach to HCV treatment. Recognition of disease process as systemic viral infection rather than as liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Comparison of high initial and fixed-dose regimens of interferon-alpha2a in chronic hepatitis C: a randomized controlled trial. French Multicenter Interferon Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Transfusion-associated chronic hepatitis C: Alpha-n1 interferon for 6 vs. 12 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Reinforced regimen of interferon alfa-2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: a multicentre randomised trial. Multicentre GER-CYT-04 Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus. A prospective, double-blind, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Quantitative assessment of hepatitis C virus RNA and IgM antibodies to hepatitis C core in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Dose increase augments response rate to interferon-alpha in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Effects of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. Japan Acute Hepatitis Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Interferon as treatment for acute hepatitis C. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Interferon therapy for acute hepatitis C viral infection--a review by meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00271.X

10.1046/J.1365-2893.2001.00271.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11155152%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference